Johnson & Johnson (JNJ)
After hours:
| Previous close | 164.64 |
| Open | 164.74 |
| Bid | 165.63 x 1400 |
| Ask | 165.63 x 800 |
| Day's range | 163.82 - 165.75 |
| 52-week range | 143.13 - 168.85 |
| Volume | |
| Avg. volume | 6,880,267 |
| Market cap | 398.446B |
| Beta (5Y monthly) | 0.52 |
| PE ratio (TTM) | 25.08 |
| EPS (TTM) | 6.60 |
| Earnings date | 15 Oct 2024 |
| Forward dividend & yield | 4.96 (3.00%) |
| Ex-dividend date | 27 Aug 2024 |
| 1y target est | 171.83 |
Insider MonkeyIs Johnson & Johnson (JNJ) the Best Blue Chip Stock To Invest In According to Short Sellers?
We recently compiled a list of the 12 Best Blue Chip Stocks To Invest In According to Short Sellers. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other blue chip stocks. “Investors Need a Reason to Buy” While economic data may be scarce, every […]
PR NewswireRYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT® (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 [FOLFOX] or FOLFIRI) demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not previously received anti-epidermal growth factor receptor (EGFR) therapy. These data were presented in a mini-oral presentation at the European Society of Med
- PR Newswire
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT® (amivantamab-vmjw) combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with previously treated non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The data also reveal a favorable trend toward improved overall survival (OS) compared to chem
